Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Viridian Therapeutics, Inc.\DE files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
3.48
4
8.39
4.46
1.05
2.96
1.77
0.31
0.3
70.8
Cost of revenue
2.55
Gross profit
0.93
Research and development
13.7
19.6
30.4
34.8
28.3
56.9
101
160
238
339
Selling, general and administrative
95
61.1
95.3
Selling and marketing
1.67
General and administrative
6.77
10.9
11
11.6
13.3
25.8
35.2
95
61.1
Operating expenses
20.5
30.5
41.5
46.4
111
82.7
136
255
299
434
Operating income
-17
-26.5
-33.1
-42
-110
-79.7
-134
-254
-299
-363
Interest expense
0.1
0.38
0.87
0.84
0.51
0
0.5
1.33
2.2
4.95
Interest income
18.2
31.6
27.4
Other non-operating income
0.04
0.4
1.25
0.94
0.17
0.32
4.43
16.7
29.1
20.8
Income tax
0
Net income
-17.3
-26.5
-32.7
-41.9
-111
-79.4
-130
-238
-270
-343
EBITDA
-16.6
-26.2
-32.8
-41.7
-110
-79.6
-134
-254
-298
-363
EPS, basic
-421.89
-20.64
-16.45
-20.04
-31.13
-6.66
-4.05
-5.31
EPS, diluted
-421.89
-20.64
-16.45
-20.04
-31.13
-6.66
-4.05
-5.31
Shares, basic (weighted)
0.04
1.29
1.98
2.09
3.56
11.9
32.1
44.8
Shares, diluted (weighted)
0.04
1.29
1.98
2.09
3.56
11.9
32.1
44.8
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
22.1
47.4
32.6
24.8
45.9
42.3
156
103
99.6
212
Short-term investments
0
29.9
2
81.7
155
269
375
618
662
Receivables
0.02
1.46
0.02
0.11
Inventory
0.06
Other current assets
1.75
2.97
2.87
2.89
1.97
2.75
6.52
9.01
20.9
19.6
Total current assets
23.9
51.9
65.4
29.7
130
200
431
486
738
894
Property, plant and equipment
0.63
0.56
0.73
0.52
0.31
0.38
1.33
1.67
1.24
1.23
Lease right-of-use assets
0
0.48
1.68
1.61
1.67
2.21
2.42
Intangible assets
0
Long-term investments
0
Other non-current assets
0.26
0.05
0.05
0
0
1.49
0.98
0.6
0.5
1.54
Total assets
24.8
52.5
66.1
30.3
131
204
435
490
742
899
Accounts payable
1.01
0.91
0.57
1.1
0.67
2.33
14.2
2.24
2.14
8.68
Accrued liabilities
3.91
2.99
3.87
5.11
9.7
11
18.8
24.1
45.7
62
Deferred revenue
0
0.3
0.29
0.29
0.29
0.29
0.37
Short-term debt
0
0
Total current liabilities
6.89
3.9
6.73
10.2
10.7
13.6
33.3
26.6
47.9
70.7
Long-term debt
2.82
9.92
8
4.33
0
20.2
20.6
Lease liabilities
1.2
1.1
1
2
1.9
Other non-current liabilities
0
0.15
0.07
0
0.04
1.21
1.17
0.99
2.31
2.34
Total liabilities
9.71
14
14.8
14.5
11.2
16
40
48.4
70.8
177
Total debt
10
10
7.67
0
4.65
20.2
20.6
Paid-in capital
5.15
132
177
184
218
412
741
961
1,478
1,927
Retained earnings
-67.1
-93.6
-126
-168
-279
-358
-488
-726
-996
-1,338
Other comprehensive income
0
-0
0
-0.01
-0.16
-0.39
0.34
-0.01
0.45
Shareholders' equity
-61.9
38.5
51.3
15.8
120
188
395
442
672
722
Total equity
-61.9
38.5
51.3
15.8
120
188
395
442
672
722
Total liabilities and equity
24.8
52.5
66.1
30.3
131
204
435
490
742
899
Shares outstanding
0.06
1.51
2.06
2.32
4.23
23.9
41.3
54
81
102
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-17.3
-26.5
-32.7
-41.9
-111
-79.4
-130
-238
-270
-343
Depreciation and amortization
0.34
0.31
0.28
0.29
0.24
0.12
0.26
0.52
0.54
0.46
Stock-based compensation
0.2
2.41
3.68
3.97
3.65
14.5
19.8
67.2
42.2
44.3
Change in receivables
-0.02
-1.44
1.43
-0.08
0.1
Change in inventory
0.12
Change in payables
0.29
-0.1
-0.34
0.53
-0.43
1.66
11.5
-12
-0.07
6.56
Cash from operations
-14.8
-28.2
-26.8
-36.1
-29.8
-54.6
-93.8
-184
-232
-276
Capital expenditures
-0.25
-0.25
-0.45
-0.08
-0.04
-0.34
-0.8
-0.9
-0.51
-0.5
Purchases of investments
-1
0
-62.5
-32.7
-81.8
-188
-223
-408
-695
-579
Sales and maturities of investments
1
0
33
61
2
46.9
0
0
0
Cash from investing
-0.25
1.03
-29.9
28.2
-50.5
-74.3
-115
-94.3
-229
-37.6
Debt issued
5
15
0
28.9
Stock issued
0.21
0.31
44.5
2.28
0
114
292
15.3
69.9
63.1
Share buybacks
-0
Cash from financing
15.9
52.5
41.9
0.07
101
125
322
226
458
427
Net change in cash
25.3
-14.8
-7.76
21.1
-3.6
113
-52.8
-3.23
113
Free cash flow
-15
-28.4
-27.3
-36.1
-29.8
-54.9
-94.6
-185
-233
-277
Interest paid
0.16
0.45
0.49
0.51
0.27
0
0.29
0.89
1.82
2.15
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $20.47 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-569.7%
Operating income / revenue.
EBITDA margin
-569.0%
EBITDA (operating income + depreciation and amortization) / revenue.
Net margin
-544.1%
Net income / revenue.
FCF margin
-471.0%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-468.7%
Cash from operations / revenue.
Return on equity (ROE)
-58.4%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-35.3%
Net income / average total assets.
Return on invested capital (ROIC)
-64.4%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
456.5%
Research and development expense / revenue.
Stock-based pay / revenue
75.4%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
2.4%
Capital expenditures / revenue.
D&A / revenue
0.7%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
23,360.0%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
241.9%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
132.2%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
7.5%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
22.3%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
43.2%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
21.1%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
27.4%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
46.9%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
16.9x
Current assets / current liabilities.
Quick ratio
15.4x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
15.4x
(Cash + short-term investments) / current liabilities.
Market cap + total debt - cash - short-term investments.
P/S
32.6x
Market cap / revenue.
P/B
3.50x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
3.56x
Market cap / tangible book value, when positive.
EV/Sales
18.8x
Enterprise value / revenue.
FCF yield
-14.4%
Free cash flow / market cap.
Earnings yield
-16.7%
Net income / market cap (the inverse of P/E).
What was Viridian Therapeutics, Inc.\DE's revenue in fiscal 2025?
Viridian Therapeutics, Inc.\DE reported revenue of $70.8M for fiscal 2025, 23,359.9% higher than the year before.
Was Viridian Therapeutics, Inc.\DE profitable in fiscal 2025?
No. It reported a net loss of $342.6M.
How much free cash flow did Viridian Therapeutics, Inc.\DE generate in fiscal 2025?
Cash from operations of $276.4M minus capital expenditures of $495.0K left free cash flow of -$276.9M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.